Queisser Angela, Heeg Steffen, Thaler Michaela, von Werder Alexander, Opitz Oliver G
Institute for Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany; Tumorzentrum Ludwig Heilmeyer - Comprehensive Cancer Center Freiburg, Freiburg, Germany; Faculty of Biology, University of Freiburg, Freiburg, Germany.
Institute for Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany; Division of Gastroenterology/Hepatology, Department of Medicine, University Medical Center, Freiburg, Germany; University of Pennsylvania, Gastroenterology Division, Philadelphia, PA, USA.
Cancer Genet. 2013 Nov;206(11):374-86. doi: 10.1016/j.cancergen.2013.10.001. Epub 2013 Oct 11.
Immortalization is an important step toward the malignant transformation of human cells and is critically dependent upon telomere maintenance. Two mechanisms are known to maintain human telomeres. The process of telomere maintenance is either mediated through activation of the enzyme telomerase or through an alternative mechanism of telomere lengthening called alternative lengthening of telomeres (ALT). Whereas 85% of all human tumors show reactivation of telomerase, the remaining 15% are able to maintain telomeres via ALT. Telomerase inhibitors are already investigated in clinical trials, although the regulation as well as potential coexistence and redundancy of both telomere maintenance mechanisms during distinct steps of carcinogenesis are poorly understood. Herein, we demonstrate that telomerase activity and ALT alternate in a cell cycle dependent fashion in human esophageal epithelial cells, and can coexist in a genetically defined model of oral-esophageal squamous carcinogenesis. Moreover, we show that immortalized premalignant cells as well as cancer cells are able to switch from telomerase activation to ALT upon inhibition of telomerase. This indicates that cancer cells treated with telomerase inhibitors can use alternative and adaptive ways to maintain their telomeres and thereby escape telomere-based therapeutic strategies.
永生化是人类细胞恶性转化的重要一步,并且严重依赖于端粒维持。已知有两种机制可维持人类端粒。端粒维持过程要么通过端粒酶的激活介导,要么通过一种称为端粒替代延长(ALT)的端粒延长替代机制介导。虽然所有人类肿瘤中有85%显示端粒酶重新激活,但其余15%能够通过ALT维持端粒。端粒酶抑制剂已在临床试验中进行研究,尽管在致癌作用的不同阶段这两种端粒维持机制的调控以及潜在的共存和冗余情况仍知之甚少。在此,我们证明在人类食管上皮细胞中端粒酶活性和ALT以细胞周期依赖性方式交替出现,并且在口腔 - 食管鳞状细胞癌发生的基因定义模型中可以共存。此外,我们表明永生化的癌前细胞以及癌细胞在端粒酶受到抑制时能够从端粒酶激活转变为ALT。这表明用端粒酶抑制剂治疗的癌细胞可以使用替代和适应性方式来维持其端粒,从而逃避基于端粒的治疗策略。